NEO: financial statements from SEC — TradeAlmanac

NEO

NeoGenomics, Inc.: financial statements

Company reports as filed with the U.S. Securities and Exchange Commission.

AnnualQuarterly

Income statement

Metric	Dec 31, 2025	Dec 31, 2024
Revenue	727m	661m
Cost of revenue	413m	370m
Gross profit	314m	290m
Research and development	37m	31m
Selling, general and administrative	273m	260m
Operating expenses	430m	382m
Operating income	−116m	−92m
Pre-tax income	−110m	−81m
Income tax	−2m	−2m
Net income	−108m	−79m
Earnings per share	−0.84	−0.62
Earnings per share, diluted	−0.84	−0.62
Weighted average shares	128m	127m
Weighted average shares, diluted	128m	127m

Balance sheet

Metric	Mar 31, 2026	Dec 31, 2025	Sep 30, 2025	Jun 30, 2025	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024
Cash and equivalents	146m	160m	164m	155m	346m	367m	362m	355m
Receivables	167m	159m	155m

Cash flow

Metric	Dec 31, 2025	Dec 31, 2024
Operating cash flow	5m	7m
Depreciation and amortisation	36m	39m
Share-based compensation	41m	33m
Capital expenditure	27m	41m
Investing cash flow	−12m	13m
Financing cash flow	−200m

Amounts in USD unless stated otherwise. Sources: Nasdaq Trader, Yahoo Finance, U.S. Securities and Exchange Commission (EDGAR)